EntreMed to Present at the Rodman and Renshaw 10th Annual Healthcare ... ( ROCKVILLE Md. Nov. 7 /- EntreMed ...)

EntreMed to Present at the Rodman and Renshaw 10th Annual Healthcare Conference

Date:11/7/2008

ROCKVILLE, Md., Nov. 7 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S. Burns, President and Chief Executive Officer, will present a Company update at the Rodman and Renshaw 10th Annual Healthcare Conference, which is being held November 10-12, 2008 at the New York Palace Hotel in New York, NY. Mr. Burns' presentation is scheduled for Tuesday, November 11, 2008 at 2:25 p.m. (local time).

Mr. Burns' presentation will be web cast and, as previously announced, will serve as the Company's third quarter 2008 update. The presentation can be accessed through the Company's web site at http://www.entremed.com. An archive will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-2076, a selective angiogenic kinase inhibitor, and ENMD-1198, a novel antimitotic agent are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine news :

1. EntreMed Receives Deloitte Technology Fast 50 Award
2. EntreMed to Present at the Bio 2007 Investor Forum
3. EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study
4. EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference
5. EntreMed Reports Third Quarter 2007 Financial Results
6. EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia Models
7. EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
8. EntreMed to Present at the Jesup & Lamont Emerging Growth Stock Conference
9. Dr. Ronald E. Cape to Retire from EntreMed Board of Directors
10. EntreMed Reports First Quarter 2008 Financial Results
11. EntreMed to Present at The Rodman and Renshaw 5th Annual Global Healthcare Conference

Post Your Comments:

(Date:11/10/2009)...eimer,s Awareness Month, and the recently released... million people worldwide will have dementia by 20...nnovator with 16 independent living and assisted l...Wisconsin and Illinois, offers the following tips ... Neenah, Wis. (Vocus) Novem...

(Date:11/10/2009)... of Public Health researchers will present Nov. 10...h Association,s annual meeting in Philadelphia, in...onal recommendations that a physician screen chest...to the Emergency Department (ED). , Additional p...ts are highlighted below. , Disparities in emer...

(Date:11/9/2009)...ilsack, Governor Patrick, and Lieutenant Governor ...e/ -- In a groundbreaking move for antihunger work...ed for all of the state,s hospitals to take an act... ,, "With 554,000 people in Massachusetts now ...ference at UMass Memorial Health Care in Worcester...

(Date:11/9/2009)...ire-Asia-FirstCall/ -- Mindray Medical,Internation...facturer and,marketer of medical devices worldwide... results for the third quarter and nine months end...ations as of September 30, 2009, -- Third quart...ase of, 3.1% over the third quarter of 2008....

(Date:11/9/2009)...Federal Trade Commission Involvement Need to be Ad...swire-USNewswire/ -- Inclusion of a provision in t...62) allowing insurance agents to sell health polic...ive, but other issues remain to be addressed in th... Professional Insurance Agents (PIA). ,, The la...

[0] Top 10 Tips for Alzheimer's Caregivers [0] Some chest pain patients wait longer than 10 minutes to see ER physician [0] McGovern and Project Bread Launch Hospital Hunger Initiative [0] Mindray Announces Third Quarter 2009 Financial Results [0] PIA Says Inclusion of Agents in House Healthcare Bill is Positive, But Concerns Remain

...ad brain tumors perform worse in school than healt...ffected and girls have a harder time than boys in...ed in the issue of Neurology. Researchers say this... survivors who are at greatest risk for school fai...

...d of watery diarrhoea while over 200 were ailing f...e floods have played havoc, officials said Saturda...s including Basta, Baliapal, Bhogarai and Jaleswar...th officials were taking care of others in their r...

...akers of painkiller OxyContin agreed to pay $600 m...criminal charge of misbranding the product , one o...in such a case. Three of its current and form...d than traditional narcotics. The three execu...

...for being extra conscious in front of the camera, ...r pins looking far from perfect . The usua...both above and below her knee, making her legs loo...I suspect she works out, which is why on her thigh...

...een Patnaik Saturday ordered police to probe into ...ate's Nayagarh district, officials said . ...ths old, were found in polythene packets at Pratap... arrest has been made so far. A group of s...

...s has claimed that Chinas desire to promote eco-to...in their infancy in the Mount Huangshan Scenic Ar...ng to National Geographic, the skyrocketing infant...pectators. The study claims that this sce...

Other Medicine News:Health News:Report Shows How Children With Brain Tumors Perform at School 2 Health News:Purdue Pharma Agrees to Pay $600 Million Fine for Misbranding Oxycontin 2 Health News:Purdue Pharma Agrees to Pay $600 Million Fine for Misbranding Oxycontin 3 Health News:Purdue Pharma Agrees to Pay $600 Million Fine for Misbranding Oxycontin 4 Health News:Chinese Eco-tourism Causing Infanticide Among Tibetan Monkeys 2

Report Shows How Children With Brain Tumors Perform at School Diarrhoea Claims Three Lives in Flood-hit Orissa Purdue Pharma Agrees to Pay $600 Million Fine for Misbranding Oxycontin Strange Marks on Poshs Legs Look Horrifying Orissa CM Orders Probe into Female Foeticides Chinese Eco-tourism Causing Infanticide Among Tibetan Monkeys

(Date:11/9/2009)..., 2009 Arena Pharmaceuti...al results for the third quarter ended September 3...ocable to common stockholders in the third quarter...pared to a net loss allocable to common stockholde...or $0.76 per share, and a net loss allocable to co...

(Date:11/9/2009)...., Nov. 9 TessArae® LLC, a gl...cations, announces the launch of new integrated pr...ns that underlie human hereditary diseases. The c...ased resequencing with novel nucleotide sequence b...s screening for all targeted mutations in multiple...

(Date:11/9/2009).... 9 AMD LASERS just announced that...esse, has accepted the position of Medical Directo... for overseeing research and development of new so...mpliance for continuing education credits, authori...lications, and lecturing and seminar engagements. ...

[0] Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments [0] TessArae Delivers Lower Cost Option to Genetic Testing Market [0] AMD LASERS Names Dr. James Jesse as Medical Director

...tion Prevention Professionals With Guidelines,and ...Professionals in Infection Control and Epidemiolog...al initiatives aimed at eliminating,healthcare-ass...um,difficile-associated disease and the three infe...rvices (CMS) have classified as preventable,occurr...

...oll, Inc., a privately-held,specialty pharmaceutic...ned,phase 2 clinical trials sponsored by its wholl...investigate CollaRx(R) GENTAMICIN TOPICAL for the,... ulcers, has commenced,dosing., CollaRx GENTAMICI...Gentamicin-Collagen Sponge formulated and manufact...

Other Medicine Technology:APIC Launches 'Targeting Zero' Initiative to Eradicate C. Difficile and Infections Deemed Preventable By CMS 2 APIC Launches 'Targeting Zero' Initiative to Eradicate C. Difficile and Infections Deemed Preventable By CMS 3 Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers 2 Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers 3 Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers 4

APIC Launches 'Targeting Zero' Initiative to Eradicate C. Difficile and Infections Deemed Preventable By CMS Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers

Uncuffed Nasoral Murphy

Super Safety Magill Cuffed Pediatric ET

Cuffed Nasoral Murphy

Cuffed Nasoral Murphy Curved

Medicine Products:

Uncuffed Nasoral Murphy Super Safety Magill Cuffed Pediatric ET Cuffed Nasoral Murphy Cuffed Nasoral Murphy Curved

EntreMed to Present at the Rodman and Renshaw 10th Annual Healthcare ...( ROCKVILLE Md. Nov. 7 /- EntreMed ...),Health